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Coagulase-negative staphylococci (CNS) are the most frequently isolated bacteria from milk samples
in several studies worldwide. Despite their relative frequency, specific measures aiming at their
control are not well established. One possible measure to include in a control programme is
lactational antimicrobial treatment. The decision to perform such treatment, as well as other actions
on farm, should be based on the likelihood of financial return. A deterministic model was used to
evaluate whether performing an antimicrobial treatment during the lactation for quarters infected
with CNS was financially justifiable. Input variables for the impact of CNS on udder health were
based on a previous study by the same authors and on available literature on the subject. Prices
included in the model were based on 2009/2010 conditions in Portugal. The average result per
antimicrobial treated quarter was a net loss of E38·74. Performing a sensitivity analysis to evaluate
how systematic variation of the input variables of the model would lead to outcome changes showed
that variation in input variables nearly always led to a negative outcome, with the greatest variation in
losses observed for variation in the length of treatment and milk withdrawal period (E46·26 to
E28·49). The situations in which a net benefit was to be expected included the bulk tank somatic
cell count decreasing to a level corresponding to a premium payment or to penalties being avoided,
and the prevention of transmission of CNS in the milking parlour when the possibility of transmission
was at its highest level. For most situations, lactational treatment of CNS subclinical mastitis was not
financially justifiable.
Keywords: Deterministic model, CNS mastitis, lactational therapy.
Coagulase-negative staphylococci (CNS) are the most
frequently isolated pathogens from bovine milk samples in
several large scale surveys worldwide (Makovec & Ruegg,
2003; Tenhagen et al. 2006). Despite their relative fre-
quency, few studies have focused on risk factors that lead to
intramammary infection (IMI) with these pathogens, or on
the efficacy of specific control measures. There is evidence
that post-milking teat disinfection with certain products can
prevent new CNS infections from occurring (Foret et al.
2005), and recently a vaccine against CNS approved by the
European Medicines Agency showed a significant reduction
in the number of new mastitis cases and a significant
increase in spontaneous cure rate, when compared with a
placebo group (Noguera et al. 2010). Antimicrobial treat-
ment would seem to be an effective way to control CNS IMI
as it has been found to lead to high cure rates for clinical
mastitis (Waage et al. 2000), subclinical mastitis during the
lactation (Wilson et al. 1999), subclinical mastitis during the
dry period (Rajala-Schultz et al. 2009) and in pre-calving
heifers (Oliver et al. 2004). Despite the high cure rates re-
ported in the literature, it is questionable whether anti-
microbial treatment is an efficient way to control CNS IMI, or
even if it should be part of a control plan, because the
somatic cell count (SCC) increase that occurs when there is a
CNS IMI tends to be low (Djabri et al. 2002), and there is
some debate as to whether CNS IMI actually lead to a milk
production loss (Schukken et al. 2009). This excludes
treatment of clinical mastitis, in which animal welfare issues
also need to be taken into account.
Several economic studies that could support decision-
making have been published on different areas of udder
health including teat disinfection (Ruegg & Dohoo, 1997),
antimicrobial treatment (Steeneveld et al. 2007), breeding
strategies (Steine et al. 2008) and vaccination (Allore & Erb,*For correspondence; e-mail: ricardobexiga.apb@gmail.com
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1998). Most mastitis economic studies resort to mathemat-
ical models to predict most likely outcomes of different
strategies considering various scenarios. These models
either rely on set values for the parameters included, in
which case they are termed deterministic, or rely on pro-
bability distributions to deal with uncertainty in the systems’
behaviour, in which case they are called stochastic
(Dijkhuizen & Morris, 1997). The initial studies published
on lactational treatment of subclinical mastitis focused on
blitz therapy of Streptococcus agalactiae IMI (Yamagata
et al. 1987; Edmonson, 1989), but since then studies ad-
dressing other pathogens have been published including
Staphylococcus aureus (Swinkels et al. 2005a), Streptococ-
cus uberis and Streptococcus dysgalactiae (Swinkels et al.
2005b). These publications incorporate information derived
from scientific studies and from prices that farmers are
confronted with, allowing for a transition from scientific
evidence to practice.
Many of the input parameters used in the current study
were obtained in a previous study (unpublished obser-
vations) by our research team, which followed IMI due to
CNS over 48 weeks at 4-week intervals on 4 farms. In that
study, genotypic identification was performed to strain level,
which allowed for 111 CNS IMI to be followed through time.
A mean duration of infection of 188 d and a geometric mean
quarter SCC of 132000 cells/ml for CNS-infected quarters
were recorded.
It is important for practitioners and milk quality consult-
ants to advise the most efficient mastitis control measures,
which are farm-specific and highly dependent on the most
prevalent udder pathogens on each farm. CNS are highly
prevalent and therefore the need for specific measures for
their control is often considered. Despite its proven efficacy,
antimicrobial treatment for CNS subclinical mastitis may not
be cost efficient. The objective of the current study was to
evaluate the economic consequence of lactational anti-
microbial therapy of subclinical mastitis caused by CNS.
Material and Methods
A partial budget was used to estimate the economic effect of
treating subclinical IMI due to CNS during lactation. Partial
budgeting is a quantification of the economic consequences
of a specific change in farm procedures (Dijkhuizen &
Morris, 1997). Partial budgets include only the items of
returns and expenses that are predicted to be affected by
a particular change in management. As a deterministic
approach, partial budgeting uses discrete values instead of
the probability distributions used in stochastic modelling.
This method includes four components: extra revenue,
reduced costs, reduced revenue and extra costs. A decision
is economically justifiable if by adding extra revenue and
reduced costs and subtracting reduced revenue and extra
costs, a positive value is obtained.
The model inputs were obtained from the scientific
literature, from mean prices for Portugal in 2009–2010,
and from mean values obtained for a longitudinal study
focusing on CNS (unpublished observations). The input
parameters were estimated considering a 100-cow herd.
Inputs into the model were not rounded off for the cal-
culations, but are presented in the text as rounded off. A
summary of input variables to the model is displayed in
Table 1.
Extra revenue
This was considered potentially to include the increase in
milk production after cure and the potential benefit of a
reduction in the bulk tank SCC after treatment.
Studies that measured milk production after treatment for
subclinical mastitis found no significant improvement after
treatment of Str. uberis and Str. dysgalactiae (St.Rose et al.
2003) or of Staph. aureus and CNS (van den Borne et al.
2010b).
As for the extra revenue potentially derived from a lower
bulk tank SCC resulting from cure and reduction in
individual quarter SCC, data from our own study were
used (unpublished observations). In that study, the mean
proportion of infected quarters was 14·4% across the 4 farms
studied, which for a 100-cow herd would be equivalent to
58 infected quarters. Geometric mean SCC for CNS-infected
quarters was 132000 cells/ml, for culture-negative quarters
was 38000 cells/ml and for the bulk tank 353000 cells/ml.
Table 1. Input variables into the economic model and their
respective sources
Input variable Value Source
Extra revenue
Increased milk production
after cure
0 van den Borne
et al. 2010b
Improvement of bulk tank SCC
leading to premium payment/
avoiding penalties
0 Calculated
Total 0
Reduced costs
Prevention of new mastitis
cases
E212·26 Calculated
Prevention of culling 0 This paper
Total +E212·26
Reduced revenue
Milk discarded
Treatment period E1113·04 Calculated
Withdrawal period E856·31 Calculated
Total E1969·35
Extra costs
Cost of antimicrobial therapy E439·39 Calculated
Labour E34·85 Calculated
Diagnostic testing 0 This paper
Antibiotic residues 0 This paper
Total E474·25
Total for the herd E2231·33
Total for an individual case E38·74
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Each infected cow had on average two infected quarters with
CNS. Considering two quarters with a CNS IMI and two
quarters with no IMI and assuming equal contribution from
all quarters to the cow SCC, such an animal would have a
SCC of 85000 cells/ml. Cure after antimicrobial treatment
has been shown to lead to significant drops in quarter SCC
(van den Borne et al. 2010b), therefore one can assume that
a cured cow would have a SCC of 38000 cells/ml, the
same as the mean quarter SCC for culture-negative quarters.
A decrease of 47000 cells/ml (85000–38000) would there-
fore be obtained for a cured animal. However, cure rates for
subclinical mastitis due to CNS are not 100%. Aggregating
data from three studies on treatment of CNS subclinical
mastitis (McDougall, 1998; Wilson et al. 1999; Taponen
et al. 2006) we estimated a cure rate of 81·9% (154 cured
quarters out of 188), which means the SCC reduction would
only be 81·9% of 47000 cells/ml on the treated animals or
38500 cells/ml, considering SCC at cow level. Considering
that this reduction would occur on 29 cows (2 quarters
affected per animal, for a total of 58 quarters) the expected
reduction on bulk tank SCC would be 11000 cells/ml
(0·29×38500). Such a low reduction in bulk tank SCC
would probably not lead to improved farm gate milk price
in most situations, as this tends to occur over wider SCC
differences. Therefore it was decided to consider extra
revenue from improved bulk tank SCC to be zero.
Reduced costs
These were considered to include the prevention of culling
and the prevention of new infections.
Mastitis is one of the main reasons for culling dairy cows
across several countries, with reported figures of 3·6%
(Whitaker et al. 2000), 10·1% (Esslemont & Kossaibati,
1997) or 12·4% (Seegers et al. 1998) of culls occurring due to
mastitis. Most culls due to mastitis will probably occur
because of incurable clinical mastitis or persistently high
SCC. Either situation would be a relatively rare occurrence
with CNS, since these microorganisms usually lead to mild
clinical mastitis (Taponen et al. 2006) and to low SCC (Djabri
et al. 2002). Therefore it was considered that treatment of
subclinical mastitis due CNS would not lead to reduced
culling.
Prevention of new IMI would result from a reduced trans-
mission occurring because a proportion of the existing cases
of CNS subclinical mastitis would be cured. Transmission of
infection can be estimated by the reproductive ratio, R,
which is the product of the transmission parameter β, a
measure of a pathogen’s contagiousness and the duration of
infection τ, which is the inverse of the cure rate α (Swinkels
et al. 2005a). β is the average number of new infections
caused by an infected individual per unit of time and R is
therefore the total number of new infections caused by an
existing infection during its infectious lifetime. To estimate R
we resorted to data from our study: average duration of a
CNS IMI was 188 d (unpublished observations). As for β we
used the best case scenario for transmission of Staph. aureus
during a steady-state period with post-milking teat disinfec-
tion (Barlow et al. 2009) which corresponded to 0·0028. It is
well established that Staph. aureus frequently behaves in a
contagious manner (Barkema et al. 2006) whereas for CNS
there is evidence that the most frequent form of IMI
acquisition might be different for different species
(Taponen et al. 2008). Therefore the lowest value recorded
for transmission of Staph. aureus was used. The R obtained
was 0·53 (0·0028÷1/188), which means that without
treatment each infected quarter would on average lead to
a new infection in 0·53 other quarters. We considered that if
the IMI was cured, duration of infection would be 30 d
because it would take that long for the case to be detected,
the aetiology to be known and for treatment to be performed.
Again, only 81·9% of the cases would be cured, with
the remaining cases persisting for 188 d. On average,
infection in treated quarters would last 58·6 d
[(0·819×30 d)+ (0·181×188 d)], corresponding to an R of
0·16 (0·0028×58·6). Hence, with treatment, transmission of
infection in one quarter would be reduced from 0·53 to 0·16.
The average cost of a new infection was also estimated.
We considered that each new infection would result in
mastitis of clinical onset 5% of the times and in mastitis of
subclinical onset 95% of the times. These values were used
because there is no evidence in the literature as to how often
a new IMI due to CNS has clinical onset. Estimated values for
clinical onset of new infections are scarce in the literature
and include 5% (Jayarao et al. 1999) and 15% (Zadoks et al.
2003) for Str. uberis, which is more pathogenic than CNS.
Out of all the infections that had a subclinical onset, it was
considered that 64·5% would self-cure after the first month
of infection and the remaining 35·5% would lead to an
infection with the average 188-d infection, based on reports
by McDougall (1998). Thus, out of the new infections, 5%
would have a clinical onset, 61·3%would have a subclinical
onset that would spontaneously cure within one month and
33·7% would have a subclinical onset and last on average
188 d.
These infections would have different costs associated
with them. A clinical case would include the costs of anti-
microbial treatment (E7·63), of labour associated with the
treatment (E0·60) and of discarded milk due to adminis-
tration of antimicrobials (E34·20), for a total of E42·43. The
sections ‘Extra costs’ and ‘Reduced revenue’ contain a full
explanation of the costs of treatment and of the value of
discarded milk. No milk production loss was considered
because CNS normally lead to mild clinical mastitis. A
subclinical case that self-cured within the first month was
considered to last 15 d. Losses associated with this type of
IMI (E1·66) and the longer IMI (E20·85) were due to the
impact of increased SCC on milk production: considering
the proportion of heifers and cows affected in the herd, the
average SCC increase and the milk production losses as-
sociated with those increases as described under the section
‘Reduced Revenue’. The average cost of a new infection
would then be E10·16 [(0·05×E42·32)+ (0·61×E1·66+
0·34×E20·85)].
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If no treatment was performed, each infected quarter
would transmit the infection to 0·53 quarters. Considering
58 infected quarters, this would lead to 30 new infections,
representing a cost of E308·38. By comparison, treatment
would reduce the infection to only 9 quarters, which would
cost E96·11, corresponding to a saving of E212·26.
Extra costs
Extra costs included the costs associated with antimicrobial
therapy: cost of antimicrobials, labour, diagnostic testing
and the cost of antimicrobial residues.
Cost of antimicrobial treatment was calculated based on
data-sheet recommendations for the duration of treatment
and on prices of 11 intramammary antimicrobials sold in
Portugal at the time of the study. An arithmetic mean was
estimated for the treatment cost (E7·63), for number of
intramammary tubes (3·36) for duration of treatment (1·9 d)
and for duration of milk withdrawal period (3·5 d). Labour
costs for the act of treatment were calculated based on
employees earning twice the minimum wage in Portugal for
the year 2010 (2×E475), working 22 d a month and 8 h/d. If
one considers that each treated quarter would take 2min per
infusion, a cost of E0·60 (E0·18×3·36 tubes) in labour
could be assumed per treated mastitis or E34·85 for the
whole herd (E0·60×58 quarters).
Costs associated with diagnostic testing were considered
to be zero because the focus of the current study was the
development of a support tool when the aetiology of IMI
was already known. However, these diagnostic costs could
easily be added to the final value for each quarter. Cost of
antimicrobial residues accidentally going into the bulk tank
after treatment were also assumed to be zero.
Reduced revenue
This included the value of discarded milk due to treatment.
Milk produced during treatment was considered a complete
loss, whereas it was considered that milk in the withdrawal
period was fed to calves, a current practice among dairy
farmers, saving the equivalent volume in milk replacer costs.
Two types of milk production were estimated: a baseline
milk production, which corresponded to themilk production
when no infection was present and that was used for the
calculation of the milk production loss associated with new
cases of clinical mastitis, and a milk production for animals
affected with subclinical mastitis.
Baseline milk production was calculated considering milk
recording values for the 4 farms enrolled in our study for its
duration (12 months). Animals with a SCC<50000 cells/ml,
considered to be uninfected, had an arithmetic mean daily
milk production of 31·5 l for primiparous (35% of the
animals) and 36·9 l for multiparous (65% of the animals),
which considering the structure of the population led to an
overall average daily milk yield of 35 l/animal. Milk
production for animals with an ongoing subclinical mastitis
due to CNS was based on the previous estimated production
but discounted for the effect of the increased SCC. According
to Seegers et al. (2003) there is a daily reduction of 0·4 kg of
milk for heifers and 0·6 kg for cows, per 2-fold increase in
the SCC from a baseline of 50000 cells/ml at cow level.
Considering 2 affected quarters per cow, each with a SCC of
132000 cells/ml and 2 quarters with no infection, each with
a SCC of 38000 cells/ml, and an equal contribution in terms
of milk yield, a cow SCC of 85000 cells/ml would be
defined. This would lead to daily milk production losses of
0·28 l/heifer and of 0·42 l/cow or to a milk production of
34·6 l/d. No effect of stage of lactation on milk yield was
considered in this study, despite Hagnestam-Nielsen et al.
(2009) observing that the magnitude of daily milk loss as-
sociated with increased SCC depended on stage of lactation,
being most extensive in late lactation. There is some evi-
dence that CNS infection is not associated with days in milk
(Østerås et al. 2006) and therefore we assumed the impact
would be equally distributed throughout lactation periods.
The price of a litre of milk (E0·299) was based on the
rolling 12-month mean in mainland Portugal (Gabinete de
Planeamento e Políticas) for the year 2009. The cost of milk
replacer was based on the arithmetic mean of prices of three
milk replacers sold in Portugal at the time of the study,
considering 125 g/l of milk replacer at a price of E0·178,
each litre of milk in the withdrawal period fed to calves
would result in a loss of E0·121/l (0·299–0·178).
Treatment of subclinical mastitis due to CNS, would lead
to a loss of E19·33 (34·6 l×1·9 d×E0·299/l) through dis-
carded milk plus E14·86 being lost as milk fed to calves
during the withdrawal period (34·6 l×3·6 d×E0·12) for a
total ofE34·19. For the total number of quarters affected, this
would be E1969·35.
Treatment of mastitis of clinical onset, which would be a
reduced cost with fewer cases being transmitted, would
occur in animals with a baseline milk production. Therefore
the value of discarded milk would be slightly higher at
E34·56 [(35 l×1·9 d×E0·299)+ (35 l×3·6 d×E0·12)].
Sensitivity analysis
A sensitivity analysis is performed to evaluate how
systematic variation to the input variables of the model
(assumptions) leads to outcome changes (Dijkhuizen &
Morris, 1997). This helps determine the impact of uncertain
estimates on the outcome of decisions and allows consider-
ation of best and worst case scenarios.
Several different inputs to our model were considered
possible and their impact estimated, with two alternatives
considered for most inputs. These included antimicrobial
treatment cost and duration, cure rate for antimicrobial
treatment, price of milk, different prevalence of infection, a
change to the price of milk due to premium payment/
avoiding penalties with lowering of the bulk tank SCC and
different R values.
Antimicrobial treatment costs included the highest and
lowest available price for intramammary antimicrobial
treatment according to data-sheet recommendations
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(E3·23 and E9·30 respectively). Duration of antimicrobial
treatment and of milk withdrawal period included the
shortest (1·5+2·0 d) and the longest in duration
(2·0+5·0 d). Cure rates for antimicrobial treatment of CNS
subclinical mastitis seem not to vary much. Reported cure
rates of 81·0 (Wilson et al. 1999), 81·8 (McDougall, 1998)
and 88·9% (Taponen et al. 2006) are close to the average
value of 81·9%we used in our model, so cure rates of 70 and
of 90%were used in the sensitivity analysis. Milk prices used
in the sensitivity analysis were the highest and lowest
recorded values during the time period considered for
construction of the model, E0·336 and E0·274, respect-
ively. Different prevalence of infection included the highest
and lowest quarter-level prevalence recorded for the farms in
the previous study (unpublished observations), 34·7 and
6·4%. The possibility of a change in farm gate milk price due
to improvement in bulk tank SCC was considered, with an
improvement of E0·005 to the baseline milk price being
tested. Two different R values were considered taking into
account mean β values proposed by Barlow et al. (2009)
for major Gram-positive mastitis pathogens, including a
value for farms performing post-milking teat disinfection
(β=0·00868, R=1·63) and a value for farms not performing it
(β=0·0362, R=6·81).
Results
Net profit for antimicrobial treatment of subclinical mastitis
due to CNS was negative at E38·74 per treated quarter or
E2231·33 for a whole-farm approach, considering the
average situation in a 100-cow herd and assuming that the
aetiological agent is known.
Table 2 displays the results for the sensitivity analysis. This
showed that variation to the model inputs would nearly
always lead to negative results except in two situations: if the
decrease in bulk tank SCC was sufficient to result in an
improvement in payment class after antimicrobial treatment
had been performed, and if the number of new infections
caused by an existing infection was set at its highest, in
which case prevention of transmission through treatment
would also be highest. Different prevalence of CNS IMI at
quarter level did not lead to different financial net results per
treated quarter as the higher costs would be divided by a
higher number of quarters.
Discussion
Considering the input variables used in the present model,
antimicrobial treatment during the lactation seems not to be
economically advisable for subclinical mastitis due to CNS.
For the average situation, such treatment would lead to a net
loss ofE38·74 per treated quarter. The highest cost would be
the reduced revenue that occurs when discarding milk
during antimicrobial treatment, and feeding it to calves
during the withdrawal period. The cost of the treatment itself
was next. These costs were not offset by extra revenue,
which was actually zero, or by reduced costs, which
corresponded to the predicted reduction in the occurrence
of new mastitis cases.
Treatment of subclinical mastitis due to different udder
pathogens has been addressed in several studies. Initial
studies were performed for Str. agalactiae, a contagious
pathogen with reportedly high cure rates after antimicrobial
treatment (Yamagata et al. 1987). These authors report a gain
for treatments performed during early and mid lactation, but
a net loss for treatments performed in late lactation (over
120 d). Swinkels et al. (2005) studied the economic benefits
of treatment of subclinical mastitis due to Staph. aureus, and
found a positive or a negative effect depending on whether
the transmission between quarters was high or low,
respectively. The same authors studied the effect of treating
chronic subclinical mastitis due to Str. uberis during the
lactation through two different methodologies, a determi-
nistic and a stochastic approach. In the deterministic model,
treatment resulted in an average profit of E11·62 over no
treatment (Swinkels et al. 2005b), whereas the stochastic
model predicted a net loss of E11 when treatment was
performed (Steeneveld et al. 2007). A recently published
study on the economics of lactational treatment of sub-
clinical mastitis with different udder pathogens points to
different economic outputs, depending on whether patho-
gens involved are transmitted between animals or acquired
from the environment (van den Borne et al. 2010a).
Therefore, it would seem that even for the so-called major
pathogens, results of economic studies for lactational
therapy are not unanimous and quite often lead to net
losses. It is not surprising then that lactational therapy for
CNS, which are consideredminor mastitis pathogens, results
in a net economic loss.
As stated previously, the deterministic approach used in
this study resorts to definite predictions for quantities (e.g.
mean price of antimicrobials used, mean price of milk, etc).
Table 2. Sensitivity analysis considering possible scenarios for
different input variables
Input variable (current input value) Level
Net profit (E/
quarter)
Antimicrobial treatment cost (E7·63) E9·30 40·38
E3·23 34·42
Duration of antimicrobial
treatment+withdrawal period
(1·86+3·55 d)
2·0+5·0 d 46·26
1·5+2·0 d 28·49
Cure rate for antimicrobial treatment
(81·9%)
70% 39·28
90% 38·38
Price of milk (E0·299) E0·336 45·55
E0·274 34·01
Prevalence of infection at quarter
level (14·4%)
6·4% 38·74
34·7% 38·74
Premium payment/avoiding
penalties
E0·005/l +71·25
R value (0·53) 1·63 31·00
6·81 +5·22
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Owing to the multifactorial nature of mastitis, use of a
stochastic approach, resorting to probability distributions
to deal with uncertainty, would probably lead to a more
informative result in as far as it would provide a distribution
of potential outcomes with the possibility of separating
variability and uncertainty. Nevertheless, the quantity and
quality of data to parameterize such a model adequately
would add considerably to the complexity and duration of
the analysis, if not to render it unworkable. Given the
convincing nature of the outcome of the analyses con-
ducted, it is felt that the simple calculations used in this
study, with the essential inclusion of the sensitivity analyses,
have the advantage of being easily understood and could
plausibly be replicated in farm-specific conditions by
practitioners.
There is an on-going debate about the role of CNS as
udder pathogens with some authors considering them a
potential problem (Taponen et al. 2009) whereas others
consider them to be potentially beneficial owing to an
observed improvement in milk production (Schukken et al.
2009). Two previous studies have approached the subject of
the economic benefits of treating CNS IMI, although strictly
speaking they also included other pathogens in the analysis
(Oliver et al. 2003; Borm et al. 2006). Both these trials
studied the effects of pre-calving treatment of heifer sub-
clinical mastitis, with CNS being the most frequently isolated
udder pathogens. One such trial concluded there was no
economic benefit (Borm et al. 2006) whereas the other led to
some economic benefit through increased milk production
(Oliver et al. 2003). There are not many studies reporting on
milk yield after antimicrobial treatment of subclinical
mastitis, but the ones available are suggestive of no im-
provement in milk yield after lactational treatment for both
CNS (van den Borne et al. 2010b) and other species (St. Rose
et al. 2003). In the present study, we assumed that no
improvement in milk production would result from anti-
microbial treatment.
Effects of CNS infection on milk yield are not well
established. Some authors found that CNS IMI led to milk
production losses (Timms & Schultz, 1987; Borm et al. 2006)
whereas others found evidence of the opposite effect
(Schukken et al. 2009; Piepers et al. 2010). There is a link
between increased SCC above a certain threshold and milk
production losses (Green et al. 2006). However, publi-
cations on this subject generally consider only the SCC level
and not the pathogen involved. Some studies have addressed
the issue of milk loss associated with specific pathogens.
Grohn et al. (2004) observed higher milk production losses
associated with clinical mastitis due to Staph. aureus,
Escherichia coli, Klebsiella spp. and for samples that were
culture-negative. Schukken et al. (2009) studied records of
4200 herds and found that CNS-infected cows produced
slightly but significantly more milk (0·45 kg/d) than culture-
negative cows, whereas cows infected with a major mastitis
pathogen produced significantly less milk (between 1·6 and
3·6 kg/d depending on the agent). Reksen et al. (2007) also
studied the effect of the isolation of specific pathogens in
milk samples and test-day milk yield and found that
pluriparous cows infected with Streptococcus spp. actually
produced more milk than their culture-negative herdmates.
Judging from these studies, there is still plenty of scope
for improvement of our understanding of species-specific
impact onmilk production, without forgetting a possible role
for increased susceptibility of higher producing cows. This
is probably not easily achieved without measurement of
quarter milk production and compensatory effects, a
logistically complex task.
Another possibility for extra revenue to be gained with
treatment for subclinical mastitis due to CNS would be the
improvement in bulk tank SCC. In the initial assumptions we
considered this to be zero, because we estimated a likely
improvement of only 11000 cells/ml in the bulk tank SCC
with treatment, which would only lead to a premium being
paid or to avoidance of penalties if the bulk tank SCCwas on
the verge of a change in payment category. Were that to
occur and a premium of E0·005 be paid, then treatment
would actually lead to positive results in the conditions
considered. Different contributions of CNS to the bulk
tank SCC could potentially be included in the model, based
on cow-level bacteriology and level of bulk tank SCC
(Schukken et al. 2009). This premium payment has a
different effect than simply increasing the farm gate milk
price. When we performed the sensitivity analysis, increas-
ing the farm gate milk price led to negative results because
during antimicrobial treatments, it would lead to milk being
discarded at those prices. A premium being paid for better
quality milk would mean that the higher prices would come
after the treatments were performed, therefore not being
affected by discarded milk.
One of the parameters included under reduced costs was
prevention of new infections. Several of the assumptions
made in estimating this parameter are debatable.We initially
considered an R value (total number of new infections
caused by an ongoing infection) of 0·53, which is fairly low,
implying that infection would not sustain itself on a farm
through transmission between animals and would only
persist because of an outside reservoir of infection. There is
emerging evidence that different CNS species behave
differently in terms of the most likely source of infection
being the environment or other cows (Taponen et al. 2008),
so predominance of a certain CNS species on a particular
farm might affect this parameter. Two additional R values
were considered in the sensitivity analysis based on β values
cited by Barlow et al. (2009). If we consider the highest of
these values, with one infected quarter transmitting infection
to 6·81 quarters during its infectious lifetime, lactational
antimicrobial treatment would lead to a net profit through
prevention of transmission.
The sensitivity analysis revealed that the prevalence of
infection at quarter level would not change the outcome of
the model. Other factors would have an impact on the level
of loss consequent to treatment. Duration of treatment and of
withdrawal period would have the largest impact on the
economic result of treatment, leading to the highest and
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lowest loss when considering the longest and shortest
duration respectively. Treatment and withdrawal period
duration were according to label use of the antimicrobials
considered. The duration of treatment and choice of anti-
microbial would probably have an impact on cure rates, as
these have been reported to vary for different antimicrobials
used in the treatment of CNS mastitis (McDougall, 1998).
However, variation in the cure rates would not actually have
a major impact on the economic outcome of treatment.
Besides the direct financial loss likely to occur with
lactational treatment with antimicrobials, other potential
negative consequences need to be considered, namely
selection for antimicrobial resistance. There is much debate
around the effects of antimicrobial usage on the emergence
of antimicrobial resistance at farm level (Call et al. 2008) but
there is some evidence of such relationship, mainly through
the comparison of conventional and organic farms (Tikofsky
et al. 2003). These authors compared antimicrobial suscep-
tibility profiles for Staph. aureus from 22 organic and 16
conventional dairy herds and found differences for 7 of 9
antibiotics studied. Public perception and consumer choices
may also be affected by higher antimicrobial usage. Even
though feeding milk to calves during the antimicrobial
withdrawal period is not recommended from the point of
view of emergence of antimicrobial resistance, it was
decided to assume that farmers feed this milk to calves in
the model, as this may occur frequently.
As other pathogens come under control on farms, there is
currently much attention devoted to the impact of CNS on
udder health. Judging from our deterministic approach, it
would appear that lactational antimicrobial treatment for
subclinical mastitis due to CNS should not be part of a
control programme, as it would lead to a net financial loss in
most situations.
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Foundation for Science and Technology. The financial support of
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gratefully acknowledged.
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